Biotinylation of Membrane Proteins for Binder Selections

Benedikt T. Kuhn, Iwan Zimmermann, Pascal Egloff, Lea M. Hürlimann, Cedric A.J. Hutter, Christian Miscenic, Roger J.P. Dawson, Markus A. Seeger, Eric R. Geertsma

Published: 2021-09-03 DOI: 10.17504/protocols.io.bpinmkde

Abstract

The selective immobilization of proteins represents an essential step in the selection of binding proteins such as antibodies. The immobilization strategy determines how the target protein is presented to the binders and thereby directly affects the experimental outcome. This poses specific challenges for membrane proteins due to their inherent lack of stability and limited exposed hydrophilic surfaces. Here we detail methodologies for the selective immobilization of membrane proteins based on the strong biotin-avidin interaction and with a specific focus on its application for the selection of nanobodies and sybodies. We discuss the challenges in generating and benefits of obtaining an equimolar biotin to target-protein ratio.

Before start

Please read the full protocol before starting any steps.

Attachments

Steps

3.1 FX Cloning

1.

Design FX-cloning compatible primers targeting your gene of interest. This is most conveniently done online at the https://www.fxcloning.org https://www.fxcloning.org website using a FASTA-formatted sequence including a start and stop codon. Order the primer set optimized toward removal of stable hairpin structures ( see Note 1 ).

Note
As the N- and C-termini of most proteins are comparably long and flexible, we generally do not insert a linker sequence between the target protein and the Avi-tag. Nevertheless, should this be desired, a sequence for a linker is best introduced at this step.

2.

Amplify the gene of interest by PCR. Prepare a 50µL and add the DNA polymerase immediately prior to starting the reaction.

Use a touch-down [21] program, e.g., (1) 0h 0m 30s at 98°C;

(2) 0h 0m 10s at 98°C;

(3) 0h 0m 15s at 61°C (annealing temperature decreased by 0.5°C per cycle);

(4) 15- 30 s/kb at 72°C; repeat (2)–(4) 14 times;

(5) 0h 0m 10s at 98°C;

(6) 0h 0m 15s at 53°C;

(7) 15–30 s/kb at 72°C; repeat (5)–(7) 14 times;

(8) 0h 2m 0s at 72°C;

(9) unlimited at 10°C.

3.

Analyze the product on a preparative TAE agarose gel. Purify the relevant band using a DNA gel extraction kit and quantify the DNA spectrophotometrically.

4.

Mix 50ng with the extracted insert in a molar ratio of vector:insert of 1:5 ( see Note 2 ).

Note
Note 2: Alternatively, should subcloning of a sequence-verified open reading frame not be required, proceed with Step 10 and use the purified PCR product to replace the pINIT_cat holding the insert.

5.

Add 1µL and adjust the volume to 9µL with ultrapure water. Add 1µL and incubate for 1h 0m 0s at 37°C in a PCR machine.

6.

Heat inactivate the SapI for 0h 20m 0s at 65°C. Let the sample cool down and add 1.25µL and 1.25µL. Incubate for 1h 0m 0s at 65Room temperature.

7.

Heat inactivate the T4 DNA ligase for 0h 20m 0s at 65°C and transform 5µL to 100µL.

8.

Plate 10% and 90% aliquots on LB-agar-Cam plates and incubate 0h 20m 0s at 37°C.

9.

Use a single colony to inoculate 5mL and cultivate 0h 20m 0s. Isolate the plasmid using a miniprep kit, determine the concentration spectrophotometrically, and verify the insert by DNA sequencing using the pINIT_cat sequencing primers.

10.

Mix 50ng ( see Note 3 ) with pINIT_cat carrying the insert to a molar ratio of vector:pINIT_cat-derivative of 1:5. Add 1µL and adjust the volume to 9µL with ultrapure water. Add 1µL and incubate for 1h 0m 0s at 37°C in a PCR machine.

Note
Note 3: Should an expression and purification strategy for the protein already be established, this combination of tags and fusions proteins should guide the choice for the expression vector. We recommend the production of protein variants with N- and C-terminal Avi-tags as this may allow the presentation of different surfaces of the target protein.

11.

Heat inactivate the SapI for 0h 20m 0s at 65°C. Let the sample cool down and add 1.25µL and 1.25µL. Incubate for 1h 0m 0s at 65Room temperature.

12.

Heat inactivate the T4 DNA ligase for 0h 20m 0s at 65°C and transform 5µL to 100µL.

13.

Plate 10% and 90% aliquots on LB-agar-Amp plates. Incubate the plates 0h 20m 0s at 37°C.

14.

Use a single colony to inoculate 5mL and cultivate 0h 20m 0s at 37°C.

15.

Archive the culture as a glycerol stock at -80°C ( see Note 4 ). This stock can serve for inoculation of expression cultures based on the araBAD promoter ( see Notes 5 & 6 ).

Note
Note 4: For other expression systems that require fresh transformations for expression cultures, e.g., those based on the T7 promoter, the stock serves as a plasmid source. No additional verification by DNA sequencing is required following the subcloning of a sequence-verified open reading frame from pINIT_cat to an FX cloning expression vector.

Note
Note 5: The FX-cloning expression vectors for fused Avi-tag allow recombinant expression in E. coli under the control of the PBADpromotor with decaHis-tag. Instead of subcloning a sequence-verified ORF from pINITIAL to an FX cloning Avi-tag expression vector, PCR products can also be cloned immediately into an FX cloning Avi-tag expression vector. This requires sequence verification of each expression vector. If multiple expression vectors are constructed, subcloning from pINITIAL prevents excessive sequencing. If one aims for only a single Avi-tagged construct, we recommend starting with pBXNH3CA (Addgene #47069), which adds a cleavable N-terminal decaHis-tag and a C-terminal Avi-tag to the protein. In our hands, this vector resulted in good expression levels for a number of ABC transporters as well as maltose-binding protein (MBP) and GFP.

Note
Note 6: Should expression in alternative pro- or eukaryotic systems be preferred, the PBAD-based expression vectors may serve as facile intermediates for fusing the Avi-tag sequences.

3.2 BirA-Based In Vitro Biotinylation

16.

Recombinantly express the target protein using previously established procedures [22] ( see Note 7 ). Purify the Avi-tagged target protein ( see Note 8 )and determine the protein concentration spectrophotometrically.

Note
Note 7: If the Avi-tagged target protein is expressed in E. coli and if the Avi-tag sequence is located in the cytoplasm, the Avi-tag will be biotinylated in vivo by virtue of the natively expressed BirA. The degree of biotinylation varies from case to case (subject to availability of biotin, level of target protein overexpression and accessibility of Avi-tag), but is often incomplete. The degree of in vivo biotinylation may be increased by co-expression of BirA and supplementation of the medium with biotin [14]. However, due to the relevance of complete biotinylation of the Avi-tag, our protocol ignores in vivo biotinylation of the target within E. coli and assures full biotinylation by performing an additional in vitro step. If required, the degree of native biotinylation can be assessed as outlined in Section 3.5 .

Note
Note 8: The BirA-based biotinylation protocol describes the procedure for His-tagged target protein but can in principle be adapted to protocols involving other affinity-tags. The use of strep-tags [23] or fusions with streptavidin-binding-protein (SBP) [24] should be avoided as biotinylation of Avi-tags by endogenous BirA, which may reach a very high degree depending on the experimental conditions and target protein, will prevent elution from the respective columns.

17.

Add 3C protease to a molar ratio of 1:10 to cleave off the decaHis-tag while dialyzing the sample for 1h 0m 0s at 4°C to remove excess imidazole ( see Note 9 ).

Note
Note 9: Although BirA is inhibited by NaCl (over 100 mM) and glycerol (over 1%) [14], we generally use buffers containing 150 mM NaCl and 10% glycerol if the target membrane protein requires this for maintaining a well-folded state. We compensate for the reduced BirA activity by biotinylating for prolonged periods (overnight).

18.

Adjust the target protein concentration to 10micromolar (µM)50micromolar (µM) (either by dilution or using a concentrator unit). Add biotin to a molar ratio of target protein:biotin of 1:1.5, 5 mM ATP, 10 mM MgOAc and BirA to a molar ratio of target protein:BirA of 20:1 ( see Note 10 ). Incubate the sample 1h 0m 0s at 4°C ( see Note 11 ).

Note
Note 10: Addition of extra amount of detergent might be necessary to keep the detergent concentration well above the CMC.

Note
Note 11: The BirA-based biotinylation reaction can also be performed for 1h 0m 0s at 4Room temperature if the target protein is stable under these conditions. For most membrane proteins we recommend keeping the sample at 4°C.

19.

Remove His-tagged BirA, HRV 3C protease, and potential remaining contaminants from the sample by reverse IMAC and collect the flow-through holding the biotinylated target protein.

20.

Perform size exclusion chromatography (SEC) to remove soluble aggregates and excess of biotin from the sample ( see Note 12 ). Determine the degree of biotinylation as outlined in Section 3.5.

Note
Note 12: Removal of free biotin is often crucial for downstream processes. In case no size exclusion chromatography is performed, use dialysis or a desalting column to remove the excess biotin from the sample.

21.

Proceed with the selection of binders such as nanobodies and sybodies ( see Note 13 ) or store the target protein ( see Notes 14 & 15 ).

Note
Note 13: The outcome of the binder selection depends to a very large extent on the quality of the target protein used. Productive binder selections are expected if: (1) the SEC profile of the biotinylated target protein is monodisperse and very similar to that obtained for non-biotinylated target protein; (2) the fraction of non-biotinylated target protein is less than 10%; and (3) in case of chemical biotinylation: over-biotinylation is excluded, ideally as assessed by mass spectrometry.

Note
Note 14: If possible, the biotinylated target protein is supplemented with 10% glycerol, aliquoted, snap-frozen in liquid nitrogen, and stored at -80°C. To assess if freezing is tolerated by the target protein, compare a frozen/thawed and untreated sample by SEC. If no discernible aggregation or protein loss is observed, freezing can be considered as tolerated.

Note
Note 15: We routinely freeze biotinylated membrane proteins for storage purposes. Having thus far analyzed more than a dozen membrane proteins in this manner, we never experienced aggregation problems due to freezing. Frozen biotinylated proteins remain stable at -80°C for several years.

3.3 BirA-Based In Vivo Biotinylation

22.

Generate mammalian expression vectors for the gene of interest in pC031 or pC039 to obtain a fusion protein with an N- or C-terminal Avi-tag ( see Notes 16 & 17 ).

Note
Note 16: The preferred location of the Avi tag on the target protein depends on the quality and quantity of the fusion protein that can be obtained. Both parameters are most easily assessed by using fluorescence-detection size-exclusion chromatography (FSEC) analysis [25].

Note
Note 17: Biotinylation of Avi-tags during cultivation can be achieved in several additional expression systems [14,26,27]. These procedures also require the co-expression of BirA and growth medium supplemented with biotin.

23.

Split an Expi293 subculture ( see Note 18 ), typically grown to 3-5 × 106 cells/mL, into a 3 L Fernbach shaking flask and adjust to a final volume of 0.6L with a density of 0.7 × 106 cells/mL.

Note
Note 18: Numerous expression screenings provided the tendency that Expi293 is more successful for expressing membrane proteins. As an alternative we recommend Freestyle 293-F cells. Implementation of the latter will require small adaptations of the described workflow for which we refer to the instructions from the supplier.

24.

Incubate the culture for 72h 0m 0s at 37°C, under humidified atmosphere and 5% CO2 in a shaking incubator.

25.

On the day of the transient transfection, adjust the culture to 830mL with a density of 3.4 × 106 cells/mL by adding Expi293 medium and/or removing cells.

26.

Add 20mL (final concentration of 50micromolar (µM)) ( see Note 19 ).

Note
Note 19: Supplementing the medium with biotin is optional. Over the course of many years and targets we observed virtually complete biotinylation even in the absence of supplemented biotin.

27.

Pipet 50mL into a 100 mL sterile Schott bottle. Add 2.7mL, shake gently, and incubate for 0h 5m 0s at 37Room temperature.

28.

Pipet 50mL into a second 100 mL Schott bottle and add the two plasmid batches in a final amount of 1mg to 0.1mg, target protein expression plasmid:BirA expression plasmid, respectively. Shake gently and incubate for 0h 5m 0s at 37Room temperature.

29.

Mix the contents of both bottles, filter sterilize, and incubate for 0h 20m 0s0h 30m 0s at 37Room temperature to form the transfection complex.

30.

Add 100mL to the Fernbach shaking flask with 850mL for a final volume of 950mL. Incubate further at 37°C and 5% CO2 with mild shaking.

31.

Add sterile 5mL and 50mL from the ExpiFectamine 293 transfection kit at 16h 0m 0s20h 0m 0s post-transfection and continue incubation.

32.

Incubate for a total time of approximately 48h 0m 0s - 72h 0m 0s post-transfection depending on the most optimal condition for protein expression. Harvest the cells by centrifugation at 3000x g, flash freeze the pellet in liquid nitrogen, and store at -80°C.

33.

Purify the biotinylated Avi-tagged target protein ( see Note 8 ) and determine the protein concentration spectrophotometrically. Determine the degree of biotinylation as outlined in Section 3.5. Proceed with the selection of binders such as nanobodies and sybodies ( see Note 13 ) or store the target protein ( see Notes 14 & 15 ).

Note
Note 8: The BirA-based biotinylation protocol describes the procedure for His-tagged target protein but can in principle be adapted to protocols involving other affinity-tags. The use of strep-tags [23] or fusions with streptavidin-binding-protein (SBP) [24] should be avoided as biotinylation of Avi-tags by endogenous BirA, which may reach a very high degree depending on the experimental conditions and target protein, will prevent elution from the respective columns.

Note
Note 13: The outcome of the binder selection depends to a very large extent on the quality of the target protein used. Productive binder selections are expected if: (1) the SEC profile of the biotinylated target protein is monodisperse and very similar to that obtained for non-biotinylated target protein; (2) the fraction of non-biotinylated target protein is less than 10%; and (3) in case of chemical biotinylation: over-biotinylation is excluded, ideally as assessed by mass spectrometry.

Note
Note 14: If possible, the biotinylated target protein is supplemented with 10% glycerol, aliquoted, snap-frozen in liquid nitrogen, and stored at -80°C. To assess if freezing is tolerated by the target protein, compare a frozen/thawed and untreated sample by SEC. If no discernible aggregation or protein loss is observed, freezing can be considered as tolerated.

Note
Note 15: We routinely freeze biotinylated membrane proteins for storage purposes. Having thus far analyzed more than a dozen membrane proteins in this manner, we never experienced aggregation problems due to freezing. Frozen biotinylated proteins remain stable at 80°C for several years.

3.4 Chemical Biotinylation

34.

Recombinantly express the target protein using previously established procedures [22]. Purify the target protein and employ preparative SEC using PBS, supplemented with the required detergent, as buffer ( see Note 20 ). Determine the protein concentration spectrophotometrically.

Note
Note 20: It is very important that compounds containing primary amines are absent from the purified protein sample for chemical biotinylation. A frequent source of primary amines stems from Tris-buffers. IMAC-purified protein is not pure enough regarding biogenic amines to be used for NHS coupling.

35.

Concentrate the target protein to 50micromolar (µM) - 200micromolar (µM).

36.

Dissolve EZ-Link Sulfo-NHS-LC-Biotin in highly pure DMSO to a concentration of 10millimolar (mM) ( see Note 21 ).

Note
Note 21: The NHS moiety of EZ-Link Sulfo-NHS-LC-Biotin reacts with water and is thereby inactivated. We therefore highly recommend preparing the Sulfo-NHS-LC-Biotin solution freshly. Keep solid EZ-Link Sulfo-NHS-LC-Biotin under argon at -80°C for prolonged storage.

37.

Add EZ-Link Sulfo-NHS-LC-Biotin to the target protein in fivefold molar excess and incubate at 25°C for 0h 30m 0s under gentle agitation ( see Note 22 ).

Note
Note 22: In case the target protein is unstable at 25°C, the biotinylation reaction can be carried out at 4°C. In this case, increase the biotin-target protein ratio to 10:1 and incubate for 1h 0m 0s instead of 0h 30m 0s.

38.

Perform SEC to remove excess of biotin from the sample ( see Note 12 ).

Note
Note 12: Removal of free biotin is often crucial for downstream processes. In case no size exclusion chromatography is performed, use dialysis or a desalting column to remove the excess biotin from the sample.

39.

Determine the biotinylation pattern of the biotinylated target protein by mass-spectrometry (Fig. 1, see Note 23 )). In case mass spectrometry analysis is not available or cannot be carried out due to the target’s high molecular weight, determine the degree of biotinylation as outlined in Section 3.5.

Note
Note 23: A typical pattern contains different species containing either none, one, or several biotin moieties per target protein (Fig.1) Ideally, the non-biotinylated species should not exceed 10% of the total species (in the example of GFP labeling shown in Fig.1, non-biotinylated target accounts for around 5%). In case of over- or under-biotinylation, the biotin-target protein ratio needs to be adjusted accordingly, while keeping the target protein concentration and incubation time constant.

40.

Proceed with the selection of binders such as nanobodies and sybodies ( see Note 13 ) or store the target protein ( see Notes 14 & 15 ).

Note
Note 13: The outcome of the binder selection depends to a very large extent on the quality of the target protein used. Productive binder selections are expected if: (1) the SEC profile of the biotinylated target protein is monodisperse and very similar to that obtained for non-biotinylated target protein; (2) the fraction of non-biotinylated target protein is less than 10%; and (3) in case of chemical biotinylation: over-biotinylation is excluded, ideally as assessed by mass spectrometry.

Note
Note 14: If possible, the biotinylated target protein is supplemented with 10% glycerol, aliquoted, snap-frozen in liquid nitrogen, and stored at -80°C. To assess if freezing is tolerated by the target protein, compare a frozen/thawed and untreated sample by SEC. If no discernible aggregation or protein loss is observed, freezing can be considered as tolerated.

Note
Note 15: We routinely freeze biotinylated membrane proteins for storage purposes. Having thus far analyzed more than a dozen membrane proteins in this manner, we never experienced aggregation problems due to freezing. Frozen biotinylated proteins remain stable at -80°C for several years.

3.5 Assessing Degree of Biotinylation

41.

Mix two aliquots of 10µg with 5× SDS-PAGE sample buffer.

42.

Add streptavidin to one of the aliquots in a 1:1 molar ratio of target protein:streptavidin ( see Note 24 ).

Note
Note 24: The biotinylation of target protein can be quantified by mobility shift in SDS-PAGE upon addition of streptavidin to the sample. Streptavidin remains folded and bound to the biotinylated target protein under conventional SDS-PAGE conditions [Note 24: The biotinylation of target protein can be quantified by mobility shift in SDS-PAGE upon addition of streptavidin to the sample. Streptavidin remains folded and bound to the biotinylated target protein under conventional SDS-PAGE conditions [28]. Membrane protein samples are usually not boiled before SDS-PAGE. However, when boiling the sample is required add streptavidin afterward.]. Membrane protein samples are usually not boiled before SDS-PAGE. However, when boiling the sample is required add streptavidin afterward.

43.

Analyze the control (no addition) and test (streptavidin addition) samples in adjacent lanes on SDS-PAGE.

44.

Stain the gel with Coomassie Brilliant Blue R-250 and quantify the band intensities with the ImageJ software and calculate the degree of biotinylation ( see Notes 25 & 26 ).

Note
Note 25: Due to the tetrameric architecture of streptavidin with four biotin-binding sites, multiple protein bands may be observed, e.g., (1) free streptavidin (53 kDa), (2) streptavidin associated with a single target protein, and (3) streptavidin associated with multiple (up to four) target proteins. In our hands, it is more straightforward to use the intensity loss of the target protein band upon streptavidin addition relative to the control sample for quantification. For more precise quantification we recommend mass spectrometry to analyze the degree of biotinylation. For qualitative analysis of target protein biotinylation, western blotting using a streptavidin-HRP conjugate can be employed.

Note
Note 26: Incomplete biotinylation might be advantageous regarding oligomeric proteins. Similar to the presence of multiple biotin labels on monomeric proteins, the occurrence of multiple biotin groups per oligomeric protein complex may restrict its flexibility upon immobilization and thereby decrease the variation and amount of protein surface accessible to the binders. We recommend a pull-down of biotinylated target protein with immobilized streptavidin and compare the pull-down efficiency with the mobility shift in SDS-PAGE to quantify the biotinylation per oligomeric unit.

推荐阅读

Nature Protocols
Protocols IO
Current Protocols
扫码咨询